Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 4

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT07565623Not ApplicableNot Yet Recruiting

Prevention of AIDS With Opportunistic Infection Paradoxical IRIS

Role: collaborator

NCT04212884Completed

Functional Decline and QoL in People Aging with HIV in Asia

Role: collaborator

NCT05265507Phase 4Unknown

Comparison of Postoperative Anti-nausea and Vomiting Effect Between Glycopyrronium and Ondansetron

Role: collaborator

NCT05256459Unknown

Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma

Role: collaborator

NCT04324996Phase 1Unknown

A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19

Role: lead

NCT03478033Not ApplicableUnknown

Rifampicin vs Rifabutin in HIV/AIDS Patients Combined With Tuberculosis

Role: collaborator

All 6 trials loaded